Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
  1. 4 Open-market sale SVP, Product Development & CTO sold 5,922 shares at $50.00 ($296,100)
  2. 4 Open-market sale Chief Financial Officer sold 2,394 shares at $50.00 ($119,700)
  3. 4 Open-market sale Director sold 3,200 shares at $50.01 ($160,032)
  4. 4 Open-market sale Director sold 30,000 shares at $45.60 ($1,368,000)
  5. 4 Open-market sale Chief Financial Officer sold 7,500 shares at an average $41.75 ($313,152)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Open-market sale SVP, Product Development & CTO sold 15,552 shares at an average $43.74 ($680,248)
  13. 4 Open-market sale President and CEO sold 10,000 shares at an average $39.75 ($397,497)
  14. 4 Open-market sale SVP, General Counsel sold 5,486 shares at $42.00 ($230,412)
  15. 4 Open-market sale President and CEO sold 15,000 shares at an average $37.55 ($563,243)
  16. 4 Open-market sale President and CEO sold 15,000 shares at an average $49.49 ($742,311)
  17. 4 Open-market sale SVP, General Counsel sold 5,000 shares at an average $50.03 ($250,147)
  18. 4 Open-market sale President and CEO sold 15,000 shares at an average $52.54 ($788,088)
  19. 4 Open-market sale SVP, General Counsel sold 5,000 shares at an average $52.99 ($264,965)
  20. 4 Derivatives Options or other derivatives

Page 11 of 22 · 435 filings